[信息] 《自然—医学》撤销杜克大学肿瘤学家一篇文章

[复制链接]
查看: 2520|回复: 2
发表于 2011-1-10 15:23:28 | 显示全部楼层 |阅读模式
《自然—医学》撤销杜克大学肿瘤学家一篇文章
因数据造假而被撤;为该作者第二篇被撤论文

据Retraction Watch网站消息,近日《自然—医学》正式撤销美国杜克大学肿瘤学家Anil Potti发表在该杂志上的一篇文章。

《自然—医学》在撤稿声明中表示,“因无法重现某些关键实验结果……我们希望撤销这篇文章”,尽管其基本方法是“有效的”,但数据上的问题直接影响了结果,因“这些结果对论文结论很重要,所以我们正式撤销这篇文章”。

据悉,这是Potti的第二篇被撤销文章,之前被撤销的一篇文章发表在《临床肿瘤学期刊》(Journal of Clinical Oncology)上。(科学网 张笑/编译)
回复

使用道具 举报

 楼主| 发表于 2011-1-10 15:24:07 | 显示全部楼层
美国杜克大学一肿瘤学家因造假而引咎辞职
曾因伪造简历被勒令停职;校方称已启动程序撤销其论文


据《科学》网站消息,因论文涉嫌造假而被调查其学术不端行为,美国杜克大学的肿瘤学家Anil Potti日前正式从该校辞职。

Anil Potti曾在数家著名期刊发表有关基因标签的文章,因其结果无法重复而遭到质疑。在《癌症通讯》(The Cancer Letter)揭发Potti伪造简历谎称自己是“罗德学者”的行为后,杜克大学勒令其行政停职。

目前,《临床肿瘤学期刊》(Journal of Clinical Oncology)已撤销Potti的一篇文章,而杜克大学也于11月19日表示已启动程序要求撤销Potti另一篇发表在《自然—医学》上的论文。(科学网 张笑/编译)
回复 支持 反对

使用道具 举报

 楼主| 发表于 2011-1-10 15:25:26 | 显示全部楼层
Duke Scientist Under Investigation Resigns
by Jennifer Couzin-Frankel on 19 November 2010, 4:35 PM | Permanent Link | 0 Comments
Email Print | More
Previous Article Next Article A Duke University oncologist who had been the focus of a misconduct investigation has resigned from the university. Anil Potti had published papers in prominent journals identifying gene signatures in tumors that could predict how a patient would respond to treatment. But his work came under scrutiny after two biostatisticians at M.D. Anderson Cancer Center in Houston, Texas, spent years trying and failing to replicate it. The case broke wide open this summer when The Cancer Letter discovered that Potti had falsely claimed to have won a Rhodes scholarship. Duke placed Potti on administrative leave soon after.

Separately, the Journal of Clinical Oncology yesterday retracted one of the papers in question, by Potti and co-author Joseph Nevins, a cancer geneticist. “The authors wish to retract this article because they have been unable to reproduce the experiments,” the notice read. Duke said today that it has “initiated a process” to request retraction of another paper by Potti, which appeared in Nature Medicine.

The Duke case has also brought scrutiny to efforts to use tumor gene patterns to predict prognosis or response to treatment. Duke opened clinical trials that relied on Potti’s work even as others were expressing concerns about their accuracy. Those trials have since been halted, but the Institute of Medicine is setting up a panel to study clinical use of these gene signatures. That’s still in the works.
回复 支持 反对

使用道具 举报

精彩图文
Copyright;  © 新科学想法 2016-2017   浙公网安备 33010202000686号   ( 浙ICP备09035230号-1 )